Cargando…
Efficacy and safety of fenofibrate add-on therapy in patients with primary biliary cholangitis refractory to ursodeoxycholic acid: A retrospective study and updated meta-analysis
Background: Ursodeoxycholic acid (UDCA) is currently used for the treatment of primary biliary cholangitis (PBC), but some people do not respond well to UDCA. It reported that the combination of fenofibrate and UDCA can improve the clinical indices in these patients. However, more high-quality evide...
Autores principales: | Guoyun, Xuan, Dawei, Ding, Ning, Liu, Yinan, Hu, Fangfang, Yang, Siyuan, Tian, Hao, Sun, Jiaqi, Yang, Ang, Xu, Guanya, Guo, Xi, Chen, Yulong, Shang, Ying, Han |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468667/ https://www.ncbi.nlm.nih.gov/pubmed/36110537 http://dx.doi.org/10.3389/fphar.2022.948362 |
Ejemplares similares
-
Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid
por: Ding, Dawei, et al.
Publicado: (2022) -
Immunoglobulin M: A Neglected Serum Biomarker in Treatment‐Naive Primary Biliary Cholangitis With Normal Alkaline Phosphatase
por: Ding, Dawei, et al.
Publicado: (2022) -
A randomized, controlled trial on fenofibrate in primary biliary
cholangitis patients with incomplete response to ursodeoxycholic
acid
por: Li, Chunlei, et al.
Publicado: (2022) -
Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion
por: Yang, Chunmei, et al.
Publicado: (2022) -
Integrative bioinformatics analysis and experimental validation of key biomarkers for risk stratification in primary biliary cholangitis
por: Tian, Siyuan, et al.
Publicado: (2023)